For decades, the standard for success in treating depression has been a simple reduction in symptoms. But for the millions of patients living with treatment-resistant depression (TRD), a reduction is not the same as recovery. Johnson & Johnson is now betting that the path to market dominance for its nasal spray, Spravato, lies in moving the goalposts from mere symptom management to sustained remission.

At the recent Psych Congress Elevate, the company presented a new analysis of six clinical trials that places remission rates front and center. By focusing on the Montgomery-Åsberg Depression Rating Scale (MADRS) score of 10 or below, J&J is attempting to differentiate Spravato from a crowded field of oral antidepressants that often fail to move patients past the threshold of moderate depression.

The Remission Gap in Psychiatry

Remission is notoriously difficult to achieve in TRD. According to the landmark STAR*D study, once a patient fails their first antidepressant, the probability of achieving remission on subsequent treatments drops precipitously, often falling to roughly 14 or 15 percent.

"The moment you go to a second antidepressant, the remission rate drops sharply," said Rakesh Jain, MD, MPH, a clinical professor of psychiatry at Texas Tech University School of Medicine and lead author of the analysis. "It’s a very sharp drop. The numbers look abysmal, or they don’t separate from placebo."

Jain argues that the industry has historically avoided highlighting remission data because the results for many standard treatments are underwhelming. By pulling together data from double-blind, open-label, and comparative studies, J&J is attempting to provide a more comprehensive picture of how esketamine performs in both controlled settings and real-world clinical practice.

Why the Shift to Monotherapy Matters

Spravato’s trajectory has been steady but deliberate. Since its 2019 approval as an add-on therapy, the drug has grown into a blockbuster, generating $1.7 billion in sales last year. Wall Street analysts project that figure could climb to $2.3 billion in 2026, fueled in part by the FDA’s January 2025 decision to approve the drug as a monotherapy.

This shift is critical for clinicians. By removing the requirement to pair the nasal spray with a conventional oral antidepressant, J&J has simplified the treatment protocol. The new data presented at Psych Congress Elevate serves as the clinical backbone for this change, aiming to convince skeptical providers that Spravato can hold patients in remission over the long term, rather than just providing a temporary lift.

The Challenge of Durability

Achieving remission is only the first hurdle. The more significant challenge in psychiatry is durability—keeping patients in that state for years. Jain emphasizes that the goal of the current analysis is to demonstrate that Spravato can maintain these gains, a claim that, if validated by long-term real-world evidence, would fundamentally alter the treatment landscape for the estimated 2.8 million Americans who fail to respond to standard care.

Key Takeaways

  • Redefining Success: J&J is shifting its marketing focus from symptom reduction to remission, defined as a MADRS score of 10 or below.
  • Market Growth: With the FDA now clearing Spravato as a monotherapy, the company is targeting a larger segment of the 2.8 million Americans struggling with TRD.
  • Data Transparency: The new analysis aggregates data from six trials to counter the industry trend of omitting remission data, which often shows poor results for traditional antidepressants.

What Experts Say

Clinicians are watching to see if this data translates into broader adoption among primary care providers and psychiatrists who have been hesitant to embrace a nasal spray delivery system. While the efficacy data is compelling, the logistical burden of administering Spravato in a clinical setting remains a factor in its long-term growth.

As J&J prepares for its next quarterly earnings call, the focus will shift from clinical posters to commercial execution. The company’s ability to convert this remission data into a standard of care will determine whether Spravato becomes the default choice for patients who have exhausted their options with oral medications. The next major test will be whether the company can sustain this momentum through 2026 as it faces increased scrutiny over the accessibility and cost of the treatment.

This article is for informational purposes only. Always consult a qualified healthcare professional before making any medical decisions.